Population Pharmacokinetics of Selumetinib and Its Metabolite N‐desmethyl‐selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low‐Grade Gliomas

Selumetinib (AZD6244, ARRY‐142886), a mitogen activated protein kinases (MEK1 and 2) inhibitor, has been granted orphan drug designation for differentiated thyroid cancer. The primary aim of this analysis was to characterize the population pharmacokinetics of selumetinib and its active metabolite N‐...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, YT, Daryani, VM, Patel, P, Zhou, D, Fangusaro, J, Carlile, DJ, Martin, PD, Aarons, L, Stewart, CF
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5445231/
https://www.ncbi.nlm.nih.gov/pubmed/28326681
http://dx.doi.org/10.1002/psp4.12175

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5445231/
https://www.ncbi.nlm.nih.gov/pubmed/28326681
http://dx.doi.org/10.1002/psp4.12175

Ejemplares similares